¼îÐÔ³ÉÏËάϸ°ûÉú³¤Òò×Ó´ÙÉñ¾­ÔÙÉúµÄÑо¿½øÕ¹

À´Ô´£ºÑ°Ò½ÎÊÒ©Íø¡¡Ñ°Ò½ÎÊÒ©Íø

ÍÆ¼öÔĶÁ
     Íõ·Ç ÎÌÁú½­ ÀîÖ÷Ò» 2004-7-31 16:50:00 ÖлªÏÔ΢Íâ¿ÆÔÓÖ¾1999ÄêµÚ1ÆÚ

    1975ÄêGospodarowiczÊ×Ïȱ¨µÀÔËÓÃÀí»¯·½·¨´ÓÅ£µÄ´óÄԺʹ¹ÌåÖзÖÀë´¿»¯³ö¼îÐÔ³ÉÏËάϸ°ûÉú³¤Òò×Ó(Basic Fibroblast Growth Factor£¬bFGF )¡£80Äê´ú£¬bFGFµÄ°±»ùËáÐòÁеõ½³ÎÇå¡£90Äê´ú£¬¹úÄÚÍâÏà¼ÌÔËÓûùÒò¹¤³Ì·½·¨³É¹¦»ñµÃÖØ×ébFGF£¬ÓÐÁ¦Íƶ¯Á˹ØÓÚbFGFµÄÑо¿¡£ÏµÁÐÑо¿Ö¤Êµ£¬bFGFÄܴ̼¤ºÍµ÷½ÚѪ¹ÜÄÚÆ¤Ï¸°û¡¢ÉÏÆ¤Ï¸°û¡¢³É¼¡Ï¸°û¡¢³É¹Çϸ°ûºÍÉñ¾­½ºÖÊϸ°ûµÈ¶àÖÖÆðÔ´ÓÚÖÐÅ߲㡢Éñ¾­ÍâÅß²ãµÄϸ°û·Ö»¯ÔöÖ³£¬ÔÚÅßÌ¥·¢Óý¡¢×éÖ¯ÓúºÏÖÐÆðÖØÒª×÷Óá£Éñ¾­·½Ã棬¹ØÓÚbFGFµÄÑо¿¼¯ÖÐÔÚÖÐÊàÉñ¾­£¬·¢ÏÖÆäÉñ¾­»îÐԹ㷺£¬Äܱ£»¤Éñ¾­Ôª£¬´Ù½øÍ»ÆðÔöÉú£¬ÌáʾÔÚÖÜΧÉñ¾­ÔÙÉú·½ÃæµÄÑо¿ÒâÒå¡£Ïֲο¼½üÄêÀ´bFGFÓëÉñ¾­ÔÙÉúµÄÏà¹ØÎÄÏ××÷Ò»×ÛÊö¡£

    Ò»¡¢ÄÚÔ´ÐÔbFGFÕý³£Çé¿öϵıí´ïºÍÉñ¾­ËðÉ˺óµÄ±ä»¯

    (Ò»)ÖÐÊàÉñ¾­£ºÕý³£Çé¿öÏ£¬ÄÚÔ´ÐÔbFGFÒÔ΢Á¿·Ö²¼ÓÚÄÔ¡¢´¹ÌåºÍÏÂÇðÄÔµÈÆ÷¹Ù£¬ÒÑ֤ʵÐÇÐνºÖÊϸ°û¡¢´¹ÌåÂËÅݼ°²¿·ÖÉñ¾­Ï¸°ûÄÜ·ÖÃÚbFGF£¬ÔÚº£ÂíÆ¤ÖÊ¡¢ÖÐÄÔ¡¢ÎÆ×´ÌåºÍСÄÔ¿ÅÁ£Ï¸°û¾ùÓÐÆäÊÜÌå¡£Éñ¾­ËðÉ˺ó£¬ÔçÆÚ¾ÍÄܹ۲쵽ÄÚÔ´ÐÔbFGF±í´ïÔö¶à£¬ÊÇÉñ¾­ËðÉ˺óÔçÆÚ·´Ó¦Ö®Ò»¡£

    Ò¶ÖîéÅÓÃÔ­´úÅàÑøµÄ´óÊó´óÄÔÐÇÐνºÖÊϸ°û×÷³É»úеËðÉËÄ£ÐÍ£¬¹Û²ì·¢ÏÖbFGFÔÚËðÉ˺ó2Сʱ¿ªÊ¼±í´ï£¬12Сʱ´ï¸ß·å£¬2Ììºó¿ªÊ¼»ØÂ䣬ÐÇÐνºÖÊϸ°û°ûÌå·Ê´ó£¬Í»Æð´Ö´ó¡£´Þ½¨ÖÒÔËÓÃNorthernÔÓ½»¡¢×é֯ѧ·½·¨¶¯Ì¬¹Û²ì´óÊó­ÄÔÃÖÂþÐÔËðÉ˺óbFGFµÄ»ùÒò±í´ïºÍ×é֯ѧ¸Ä±ä£¬½á¹û·¢ÏÖÇá¶ÈËðÉ˺ó12Сʱ£¬ÖضÈËðÉ˺ó4Сʱ£¬bFGF»ùÒò±í´ïÔö¼Ó£¬¾ùÓÚµÚ3Ìì´ïµ½¸ß·å¡£Grothe¡²1¡³Ñо¿¼¹ËèÉñ¾­½ÚbFGF¼°Æä¢ñÐÍÊÜÌå(FGFR-1)µÄ±í´ïʱ·¢ÏÖ£¬Õý³£Çé¿öÏ£¬bFGFºÍFGFR-1µÄmRNAÔÚ¼¹Éñ¾­½Ú¾ùÓбí´ï£¬Ô­Î»ÔÓ½»ÏÔʾÐÇÐνºÖÊϸ°û²úÉúbFGF£¬¶ø¸Ð¾õÉñ¾­Ôª±í´ïFGFR-1£¬ÌáʾÅÔ·ÖÃÚ×÷Óã»×ø¹ÇÉñ¾­ËðÉ˺ó£¬L4¡«6¸Ð¾õÉñ¾­ÔªbFGFµÄ±í´ïÔÚ1ÌìÄÚ¼´Éϵ÷£¬7Ìì´ï¸ß·å£¬28Ììºó»Ö¸´£¬FGFR-1µÄ±ä»¯Ôò²»Ã÷ÏÔ¡£

    (¶þ)ÖÜΧÉñ¾­£ºGrothe¡²1¡³ºÍMeisinger¡²2¡³1997Ä걨µÀÁËbFGF¼°ÆäÊÜÌåÔÚÖÜΧÉñ¾­µÄ±í´ïºÍËðÉ˺ó±ä»¯µÄÑо¿½á¹û£¬¶ø´Ëǰ¸ÃÁìÓòδ¼û±¨µÀ¡£¸ÃÑо¿·¢ÏÖ£¬Õý³£Çé¿öÏ£¬´óÊó×ø¹ÇÉñ¾­FGFR-1 mRNA±í´ï¸ßÓÚbFGF mRNA¡£×ø¹ÇÉñ¾­ËðÉ˺ó£¬FGFR-1ºÍbFGFµÄmRNAÔÚËðÉËÔ¶¡¢½ü¶Ë¾ùÓÚ²»Í¬µÄʱÏàµãÉϵ÷£¬²¢ÓÐʱ¼äÒÀÀµÐÔ£»bFGFµÄ±í´ï¾ßÓÐ×ÔÉíÕý·´À¡Ìص㣬ÇÒ²»Ó°ÏìFGFR-1¡£ÕâһʵÑé˵Ã÷£¬ÓëÔÚÖÐÊàÉñ¾­Ò»Ö£¬ÄÚÔ´ÐÔbFGF±í´ïÔö¶àͬÑùÊÇÍâÖÜÉñ¾­ËðÉ˺óµÄÔçÆÚ·´Ó¦¡£

    Éñ¾­ËðÉ˺óbFGF±í´ïÉϵ÷µÄÒâÒåÊÇʲô?²»ÉÙѧÕß½«bFGFÔËÓÃÓÚÉñ¾­Ï¸°ûÅàÑøºÍÉñ¾­ËðÉËÄ£ÐÍ£¬·¢ÏÖbFGF¾ßÓй㷺µÄ´ÙÉñ¾­ÔÙÉú×÷Óã¬ÌáʾbFGF±í´ïÔö¶àÊÇÉñ¾­ËðÉ˺óµÄÐÞ¸´·´Ó¦£¬ÇÒ¿ÉÄܾßÓÐʼ¶¯ÒâÒå¡£

    ¶þ¡¢ÍâÔ´ÐÔbFGF´Ù½øÉñ¾­ÔÙÉú

    (Ò»)ÖÐÊàÉñ¾­

    (1)ÀëÌåÊÔÑ飺¶ËÀñÈÙÔÚÔ­´úÅàÑøµÄ´óÊóÅßÌ¥ÖÐÄÔÉñ¾­Ï¸°ûÖмÓÈëbFGF£¬¹Û²ì·¢ÏÖϸ°û΢Íż¯ÂäÐγÉÂÊÃ÷ÏÔÔö¼Ó£¬²»Í¬¼ÁÁ¿µÄbFGF±íÏÖÁ¿Ð§¹ØÏµ£¬Í¼Ïñ·ÖÎö¼ûÉñ¾­Ï¸°ûÍ»ÆðÔö¶à£¬Á¬½Ó·á¸»³ÊÍø×´¡£MiyagawaÔËÓÃbFGFÓÚÔ­´úÅàÑøµÄº£ÂíÉñ¾­ÔªÖáÍ»ËðÉËÄ£ÐÍ£¬¹Û²ì·¢ÏÖʵÑé×é½Ï¶ÔÕÕ×éÖáÍ»ÔöÉú¡¢Í»ÆðÔö¶à¡£Himmelseher¡²3¡³½øÒ»²½Ñо¿Á˲»Í¬Å¨¶ÈµÄbFGF¶ÔÈçÉÏÄ£Ð͵Ä×÷Ó㬽á¹ûδÓÃbFGFµÄ¶ÔÕÕ×éÉñ¾­Ôª´æ»î65%£¬ÔËÓò»Í¬¼ÁÁ¿bFGFµÄÊÔÑé×éÉñ¾­Ôª±äÐÔ¾ù¼õÉÙ£¬10 mg/L×é´æ»îÉñ¾­Ôª´ï85%£¬Éñ¾­Í»ÆðÒàÔö¶à¡¢Ôö³¤¡£

    ÓÉÉÏÊöÊÔÑé¿É¼û£¬bFGFÄÜ´Ù½øÅàÑøµÄÉñ¾­Ï¸°ûÔöÉú£¬Éñ¾­Ï¸°ûËðÉ˺óÔËÓÃbFGF£¬±äÐÔËÀÍö¼õÉÙ£¬Éñ¾­Í»ÆðÔöÉú£¬ËµÃ÷bFGFÔÚÌåÍâ¾ßÓдٽø¡¢±£»¤Éñ¾­Ï¸°ûµÄ×÷Óá£Malgrane¡²4¡³Ñо¿´óÊ󱳸ùÉñ¾­½ÚÉñ¾­Ôª¶ÔÉñ¾­¶¾ÐÔÒ©ÎïµÄ·´Ó¦Ê±·¢ÏÖ£ºbFGF²»µ«Äܴ̼¤ÖáÍ»ÔÙÉú£¬¶øÇÒÌáǰ24СʱÔËÓÿÉÒÔÏÔÖø¼õÉÙÉñ¾­¶¾ÐÔÎïÖʵÄ×÷Óã¬Õâ´ÓÁíÒ»¸ö½Ç¶È˵Ã÷ÁËbFGF¶ÔÉñ¾­Ï¸°ûµÄ±£»¤¡¢Î¬³Ö×÷Óá£

    (2)ÔÚÌåʵÑ飺bFGF±£»¤ÖÐÊàÉñ¾­Ï¸°û¡¢´Ù½øÍ»ÆðÔö³¤µÄЧӦÔÚÌåÄÚÒàµÃµ½Ö¤Êµ¡£Íô´º·çÔËÓÃbFGFÖÎÁƳÉÄê´óÊó´óÄÔÆ¤ÖÊËðÉËÄ£ÐÍ£¬ÓÚËðÉËÊõÖкÍÊõºó·Ö´Î¸øÓèbFGF£¬Êõºó40ÌìÈ¡²Ä×÷ÌåÊÓѧ·ÖÎö£¬½á¹ûʵÑé×é´æ»îÉñ¾­ÔªÏÔÖø¶àÓÚ¶ÔÕÕ×é¡£Miyamoto¡²5¡³·Ö±ðÔËÓÃbFGF¡¢Éñ¾­Éú³¤Òò×Ó(Nerve Growth Factor£¬NGF)ÓÚ´óÊó´óÄÔµ¥²àÉ¡ñ·Áþ²¿ÇжÏÄ£ÐÍ£¬·¢ÏÖbFGFºÍNGF¾ùÄܴ̼¤º£ÂíÒÒõ£µ¨¼îõ¥Ã¸ÑôÐÔÏËάÉú³¤£¬NGF×é½öΪϸÏËά¶øbFGF×é´Ö¡¢Ï¸ÏËά¾ùÓС£

    Nakahara¡²6¡³½«¾­»ùÒòÐÞÊκó¿É·ÖÃÚbFGFµÄ³ÉÏËάϸ°ûÒÆÖ²ÓÚ´óÊó¼¹ËèËðÉËÄ£ÐÍÖÐÑë»ÒÖÊ´¦£¬·¢ÏÖ2ÖÜÖÁ6Ôº󣬱³²àÇøµÄ¸Ð¾õÉñ¾­¡¢È¥¼×ÉöÉÏÏÙËØÄÜÉñ¾­¾ùÓÐÏËά³¤ÈëÒÆÖ²Ï¸°û£¬ÌáʾbFGF¾ßÓÐÓÕÉñ¾­»îÐÔ¡£

    (¶þ)ÖÜΧÉñ¾­£ºbFGF¼°ÆäÊÜÌåÔÚÖÜΧÉñ¾­µÄ±í´ïÉв»Çå³þ£¬Aebischer¡¢Laquerriere¼´Òѳ¢ÊÔÔËÓÃÌî³äbFGFµÄС¹ÜÌ×½Ó×ø¹ÇÉñ¾­È±Ëð£¬Êõºó4ÖÜÐÐ×é֯ѧ¡¢µçÉúÀí¼ì²é£¬·¢ÏÖʵÑé×éÓÐÉñ¾­ÏËάÉú³¤£¬¶ø¶ÔÕÕ×éûÓС£ËäÈ»ÓÐÉñ¾­ÏËάÉú³¤²¢²»¾Í˵Ã÷Éñ¾­³É¹¦ÔÙÉú£¬µ«ÒÑÌáʾÁËbFGFÖ±½Ó»ò¼ä½Ó´Ù½øÖáÍ»Éú³¤µÄ¿ÉÄÜ¡£¹ÊbFGFµÄ×÷ÓÃЧÄÜ¡¢·Ö×ÓÉúÎïѧ×÷ÓûúÖÆ£¬ÖµµÃÉîÈëÑо¿¡£

    Ñ©Íúϸ°û(Schwann­¸s cell£¬SC)·ÖÁÑÔöÖ³ÊÇÖÜΧÉñ¾­ÔÙÉúµÄÖØÒª»·½Ú£¬ÔöÖ³µÄSCÍÌÊɱäÐÔ²úÎÐγÉË÷´øÒýµ¼ÔÙÉúÖáÍ»³¤ÏòÔ¶²à£¬²¢·ÖÃÚ¶àÖÖÉñ¾­ÓªÑø¡¢Ç÷»¯Òò×Ó£¬Ê¹ÖáͻѸËÙ¡¢×¼È·Éú³¤¡£ÌåÍâÅàÑøµÄSCÒÆÖ²µ½Éñ¾­ÔÙÉúÊÒÖÐÄÜ´Ù½øÉñ¾­Éú³¤ÒÑΪÊÔÑé֤ʵ¡£ÔÚÅàÑøSCµÄ¹¤×÷ÖУ¬Rater¡¢Dong¡¢¹¨Ñ×Åà¾ù·¢ÏÖbFGFÄÜ´Ù½øSC·ÖÁÑÔöÖ³£¬¹¨ÊÏÔËÓÃÁ÷ʽϸ°û¼Æ¹Û²ìFGF¡¢NGF¡¢ÏËÁ¬µ°°×ºÍÉñ¾­ÔÙÉúÌõ¼þÒº¶ÔSCÌåÍâϸ°û¶¯Á¦Ñ§µÄÓ°Ï죬·¢ÏÖ8ÌìºóFGF×éSCÔöÖ³×îÏÔÖø£¬´ï8±¶ÒÔÉÏ£¬¶øNGF¶ÔSC·ÖÁÑÔöÖ³²»Æð×÷Óá£ËäÈ»SC³¬³£ÔöÖ³µÄÒâÒåѧÕßÃÇÉÐÎÞ¶¨ÂÛ£¬µ«¶ÔSCÔöÖ³ÆÚÒѹýµÄ³Â¾ÉÐÔÉñ¾­ËðÉË£¬´Ù½øSCÔöÖ³¶ÔÉñ¾­ÔÙÉúºÜ¿ÉÄÜÓÐÖØÒªÒâÒå¡£Òò´Ë£¬Ó¦½øÒ»²½ÑéÖ¤bFGFÄÜ·ñ´Ù½øÔÚÌåSCÔöÖ³¼°ÔöÖ³ºóµÄ¼Ì·¢Ð§Ó¦¡£

    Ñª¹Ü·¢Éú¶ÔÉñ¾­ËðÉ˺󴴿ÚÓúºÏ¡¢Éñ¾­ÔÙÉúµÄÒâÒåÖØ´ó£¬È»Æä³õʼ½éÖÊÈÔδÍêÈ«²ûÃ÷¡£Baffour¡²7¡³ÔÚÍÃÏÂÖ«¼±ÐÔȱѪģÐÍÔËÓÃbFGF£¬·¢ÏÖÖÎÁÆ×鼡Èâ»îÁ¦¡¢¼¡ÄÚѪÑõº¬Á¿¡¢Ã¿Æ½·½ºÁÃ×ëϸѪ¹ÜÊýºÍÿ¼¡ÏËάëϸѪ¹ÜÊý¾ùÃ÷ÏÔ¸ßÓÚ¶ÔÕÕ×é¡£ÌáʾbFGFÄÜ´Ù½øÎ¢Ñ­»·Öؽ¨¡£Nissen¡²8¡³ÊÕ¼¯Êõºó´´¿ÚÄÚÒºÌå·ÖÎö·¢ÏÖ£¬Ñª¹ÜÄÚÆ¤Éú³¤Òò×Ó(Vascular Endothelial Growth Factor£¬VEGF)Ũ¶ÈÊõ±ÏÎޱ仯£¬ºó7ÌìÖð½¥Éý¸ß£¬¶øbFGFŨ¶ÈÊõ±Ï¼´Éý´ï¸ß·å£¬3Ììºó½µÖÁѪ½¬Å¨¶È£»¸÷ʱÏàµã´´ÊÒÄÚÒº¾ù¶ÔÄÚÆ¤Ï¸°ûÓÐÇ÷»¯ÐÔ£¬ÄÜÒý·¢Éñ¾­¡¢Ñª¹Ü·´Ó¦£¬Êõ±Ï²ÉÈ¡µÄ´´ÊÒÄÚÒº£¬¾­VEGFµÄ¿¹ÌåÖкͺóÈÔ¾ßÇ÷»¯ÐԺʹÙѪ¹Ü·¢ÉúÄÜÁ¦£¬Êõºó3ÖÁ6Ìì²ÉÈ¡µÄ´´ÊÒÄÚÒº£¬¾­VEGFµÄ¿¹ÌåÖкͺóÇ÷»¯ÐԺʹÙѪ¹Ü·¢ÉúÄÜÁ¦ÏÔÖø½µµÍ¡£ÌáʾbFGFÊÇѪ¹Ü·¢ÉúµÄʼ¶¯½éÖÊ£¬VEGFÔòÆð׿̷¢¶ø³ÖÐøµÄ×÷Óá£SeghzziÑо¿Ð¡Êó½ÇĤѪ¹Ü·¢Éúʱ£¬·¢ÏÖÐγÉëϸѪ¹ÜµÄÄÚÆ¤Ï¸°û±í´ïVEGF mRNAºÍµ°°×£¬ÍâÔ´ÐÔbFGF»òÉϵ÷ÄÚÔ´ÐÔbFGFÄÜÔö¼ÓVEGFµÄ±í´ï¡£ËµÃ÷VEGFµÄ±í´ïÊÜbFGFµ÷¿Ø£¬ÔËÓÃbFGFÄÜ´Ù½øÑª¹Ü·¢Éú£¬¸ÄÉÆÑª¹©¡£¶øÑª¹©µÄ¸ÄÉÆÏÔÈ»ÓÐÀûÓÚ´´¿ÚÓúºÏºÍÉñ¾­ÔÙÉú¡£

    ×ÛÉÏËùÊö£¬bFGF´Ù½øÉñ¾­ÔÙÉúµÄ×÷ÓÃÊÇ¶à·½ÃæµÄ£º(1)±£»¤Éñ¾­Ôª£»(2)´Ù½øÖáÍ»ÔÙÉú£»(3)´Ù½øSCÔöÖ³£»(4)´Ù½øÑª¹Ü·¢Éú£¬¸ÄÉÆÑª¹©Î¢Ñ­»·µÈ¡£½èÖú·Ö×ÓÉúÎïѧ¡¢ÃâÒßѧµÈµÄм¼Êõ£¬¸÷·½ÃæµÄÑо¿»¹ÔÚ²»¶ÏÉîÈë¡£µ«ÁíÒ»·½Ã棬ǿµ÷Éñ¾­ÓªÑøÐÔÖ®Í⣬Éñ¾­Ö§ÅäµÄЧӦÆ÷Ó¦ÈçºÎ¼õ»ºÍ˱ä?ÓйØÐ§Ó¦Æ÷ÓªÑøÐÔµÄÑо¿ÈÔ²»¶à¼û£¬ÖµµÃ×¢Ò⣬ÒòΪЧӦÆ÷²»¿ÉÄæÐÔÍ˱䣬ͬΪÉñ¾­ËðÉË¡¢ÓÈÆä³Â¾ÉÐÔËðÉËÐÞ¸´À§ÄѵÄÖ÷ÒªÕϰ­¡£

    Èý¡¢bFGFÓëÖÜΧÉñ¾­ÔÙÉú

    ½ü10ÓàÄêÀ´£¬ÐÂÐ˵ġ¢¿çѧ¿ÆµÄÉñ¾­ÉúÎïѧ·¢Õ¹Ñ¸ËÙ£¬¶ÔÖÜΧÉñ¾­ÔÙÉúµÄÑо¿´Óϸ°û¡¢ÑÇϸ°û·¢Õ¹µ½·Ö×Óˮƽ£¬Ìá³öÁËһЩеĸÅÄîºÍÀíÂÛ¡£ÈÏΪÉñ¾­²»Í¬ÓÚÒ»°ã×éÖ¯£¬Éñ¾­Ï¸°û°ûÌåλÓÚÖÐÊ࣬¶øÖáÍ»ÑÓÉìºÜ³¤£¬×é³ÉÖÜΧÉñ¾­£¬Éñ¾­ËðÉ˵ÄÐÔÖÊÊÇϸ°ûËðÉË¡£ËðÉ˺󲻽öÖáÍ»¶ÏÁÑ£¬»¹ÒýÆð½ü¶ËÉñ¾­Ôª»µËÀ£¬Ô¶¶ÎÉñ¾­±äÐÔ£¬Ê§Éñ¾­Ö§ÅäµÄ¸Ð¾õ¡¢Ô˶¯Ð§Ó¦Æ÷Í˱äήËõ£¬Òò´ËÉñ¾­ËðÉ˲»½öÊÇËðÉ˾ֲ¿Ò»¸öˮƽÓв¡±ä£¬»¹°üÀ¨Éñ¾­Ôª¡¢Ð§Ó¦Æ÷£¬ÊÇÈý¸öˮƽµÄ²¡±ä£¬Ö»×¢ÖØËðÉ˾ֲ¿µÄ´¦ÀíÊÇÆ¬ÃæµÄ¡£³É¹¦µÄÉñ¾­ÔÙÉúÒªÇó£º(1)±£»¤½ü¶ËÉñ¾­Ôª£»(2)ÔÙÉúÖáÍ»¿ìËÙ¡¢×¼È·³¤ÏòÔ¶¶Î£»(3)ЧӦÆ÷δ·¢Éú²»¿ÉÄæÐÔÍ˱䣻(4)ÔÙÉúÖáÍ»ÓëЧӦÆ÷Ðγɹ¦ÄÜÐÔÍ»´¥¡£SC¡¢»ùµ×ĤºÍÉñ¾­ÓªÑøÒò×Ó(Neurotrophic Factor£¬NTF)ÊÇ·¢»ÓÒÔÉÏ×÷ÓõÄÎïÖÊÒªËØ¡£NTFÊÇÖ¸Äܱ£»¤Éñ¾­Ôª£¬ºÍ/»ò´Ù½øÖáÍ»ÔÙÉúµÄÎïÖÊ£¬ÒÑÌá³öNGF¡¢½Þ×´Éñ¾­½ÚÓªÑøÒò×Ó(CNTF)¡¢ÄÔÔ´ÐÔÓªÑøÒò×Ó(BDNF)¡¢bFGFµÈ20ÓàÖÖ¡£ÖÁ½ñ£¬NGFÓÉÓÚ£º(1)ÌåÄÚÓÐÌØÒìÊÜÌ壻(2)ÌåÄÚÍâ×÷ÓþùÓÐЧ£»(3)ÖÆ±¸µÄ¿¹ÌåÄÜ×è¶Ï»îÐÔ£¬Î¨Ò»µÃµ½Ö¤Êµ£¬¶øbFGF¼°ÆäÊÜÌåÔÚÖÜΧÉñ¾­µÄ±í´ï¼°ËðÉ˺ó±ä»¯µÄÑо¿ÕýÔÚ¿ªÕ¹£¬ÆäÔÚÌåÔËÓõÄЧÄÜ¡¢¿¹Ìå×è¶ÏµÄʵÑéÒà´ý½øÐУ¬ËùÒÔÊÇÒ»ÖÖDZÔڵġ¢Î´Íêȫ֤ʵµÄNTF£¬µ«ÔÚÊÔÑéÖÐÒѾ­Õ¹ÏÖÁ˽ÏNGF´ÙÉñ¾­ÔÙÉú»îÐԹ㷺µÄÌØµã£¬³ýÓëNGFÒ»ÑùÄܱ£»¤Éñ¾­Ôª¡¢´Ù½øÖáÍ»Éú³¤Í⣬»¹Äܴ̼¤SCÔöÖ³£¬´Ù½øÃ«Ï¸Ñª¹ÜÐγɸÄÉÆËðÉËÉñ¾­¼°ÖÜΧ×éÖ¯µÄѪ¹©£¬Òò¶øÓÖÊǺÜÓÐDZÁ¦µÄ£¬Ô¤¼ÆËæ×ÅÒÔÉÏÁ½·½ÃæÑо¿µÄ½øÕ¹£¬bFGF×÷ΪһÖÖNTFµÄÐÔÖʽ«ºÜ¿ì³ÎÇ壬ΪÉñ¾­ËðÉË»¼Õß´øÀ´ÐµÄÏ£Íû¡£

    ×÷Õßµ¥Î»£º650032 ÔÆÄÏÊ¡À¥Ã÷ÊУ¬³É¶¼¾üÇøÀ¥Ã÷×ÜҽԺȫ¾ü¹Ç¿ÆÖÐÐÄ

    ²Î¿¼ÎÄÏ×

    [1] Grothe C£¬Meisinger C£¬Hertenstein A£¬et al. Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 mRNAs in spinal ganglial and sciatic nerve£ºregulation after peripheral lession. Neurosci£¬ 1997£¬76£º123-135.

    [2] Meisinger C£¬Grothe C.Differential regulation of fibroblast growth factor (FGF)-2 and FGF receptor mRNA and FGF-2 isoforms in spinal ganglial and sciatic nerve after peripheral nerve lesion. J Neurochem£¬ 1997£¬68£º1150-1158.

    [3] Himmelseher S£¬ Pfenninger E£¬ Geo-rgieff M. Effect of basic fibroblast growth factor on hippocampal neurons after axonal injury. J Trauma£¬ 1997£¬42£º659-664.

    [4] Malgrane B£¬Delree P£¬ Rigo JM£¬ et al. Imge analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture. J Neurosci Methods£¬ 1994£¬ 53£º111-122.

    [5] Miyamoto O£¬ Itano T£¬ Fujisawa M£¬ et al. Exogenous basic fibroblast growth factor and nerve growth factor enhance sprouting of acetylcholinesterase positive fibers in denervated rat hippocampus. Acta Med Okayama£¬1993£¬47£º139-144.

    [6] Nakahara Y£¬ Gage FH£¬ TuszynskiMH.Grafts of fibroblast genetically modified to secrete NGF£¬ BDNF£¬ NT-3£¬or basic FGF elicit differential responses in the adult spinal cord. Cell Transplant£¬1996£¬5£º191-204.

    [7] Baffour R£¬Berman J£¬ Farb JL£¬ et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant bFGF in a rabbit model of acute lower limb ischemia£ºdose response effect of bFGF. J Vasc Surg, 1992£¬16£º181-193.

    [8] Nissen NN£¬Polverini PJ£¬Koch AE£¬ et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol£¬ 1998£¬152£º1445-1452.
Ïà¹ØÎÊ´ð£º
  • ¼ÃÄÏÄÄÀïÓÐÂôÖØ×éÅ£¼îÐÔ³ÉÏËάϸ°ûÉú³¤Òò×Ó
  • Éñ¾­Éú³¤Òò×ÓµÄ×÷ÓÃÊÇʲô?
  • ´Ùºìϸ°ûÉú³¤ËØ×¢ÉäÌåµÄ¼Û¸ñ
  • ×ø¹ÇÉñ¾­¸î¶Ï£¬Éñ¾­ÄÜÔÙÉú³¤Âð£¿
  • Éñ¾­Éú³¤Òò×Ó×¢ÉäҺʲôµØ·½¿ÉÒÔÂòµ½?
  • ´Ù½øÒõ¾¥ÔÙÉú³¤¡¡¡¡
  • ÊóÉñ¾­Éú³¤Òò×ÓÊÇʲôҩ¸±×÷ÓôóÂð?
  • Éñ¾­Éú³¤Òò×ÓµÄ×÷ÓÃÊÇʲô?Ò»Ö§¶àÉÙÇ®?Ôõ.
  • ÄÐÈ˵ÄÄÜÔÙÉú³¤Âð£¿
  • ¶úÄ¤ÆÆÁË»áÔÙÉú³¤Âð?

  • Ïà¹Ø×ÊѶ£º
  • ³ÉÏËάϸ°ûÉú³¤Òò×ÓÐźŷÖ×ӵĽṹºÍ¹¦ÄÜ
  • ϸ°ûÒò×ÓºÍÉú³¤Òò×Ó
  • ת»¯Éú³¤Òò×Ó¦ÂÓëÐÄѪ¹ÜÖØ¹¹¹ØÏµÑо¿½øÕ¹
  • ÃÀ×îÐÂÑо¿£ºÃâÒßϸ°ûÓÐʱ»á´Ù½ø°©Ï¸°ûÉú³¤
  • ÈÕ±¾ÓÃÖ¬·¾Ï¸°ûÔÙÉúÖÐÊàÉñ¾­Ï¸°û¶¯ÎïÊÔÑé³É.
  • ÃÀ¹úÑо¿·¢ÏÖÒ»ÖÖ·Ö×Ó¿ÉÒÖÖÆÖ×Áöϸ°ûÉú³¤
  • ÎÒ¹ú¿¹°©Ò©ÒÖÖÆÎ¸°©Ï¸°ûÉú³¤Ñо¿»ñÖØÒª·¢ÏÖ
  • ¿¹°©Ò©ÒÖÖÆÎ¸°©Ï¸°ûÉú³¤Ñо¿»ñÖØÒª·¢ÏÖ
  • Âѳ²°©ÓëѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓÓйØ
  • µÂ¹ú¿ÆÑ§¼ÒÕÒµ½Ê¹ÄÔϸ°ûÔÙÉúµÄ·½·¨
  • ½¡¿µÍ¼Æ×
    ½¡¿µÉ̳Çhttp://shop.xywy.com ½¡¿µ¹ºÎïºÃÈ¥´¦
    ÓÑÇéÁ´½Ó